-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
-
Summary
-
Ambrx Biopharma Cayman, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2020 to Q4 2022.
- Ambrx Biopharma Cayman, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2022 was $81.7M, a 33.8% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)